Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cyto...
Main Authors: | Anne-Priscille Trouvin, Vincent Goëb |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-11-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/receptor-activator-of-nuclear-factor-kappab-ligand-and-osteoprotegerin-peer-reviewed-article-CIA |
Similar Items
-
Treatment of primary osteoporosis in men
by: Giusti A, et al.
Published: (2014-12-01) -
The Role of Osteoprotegerin and Its Ligands in Vascular Function
by: Luc Rochette, et al.
Published: (2019-02-01) -
RANK, RANKL and osteoprotegerin in arthritic bone loss
by: M.C. Bezerra, et al.
Published: (2005-02-01) -
Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
by: Chan Kai-Ming, et al.
Published: (2011-07-01) -
Study of the incidence of osteoporosis in patients with Sjögren’s syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system
by: Charalampos Skarlis, et al.
Published: (2018-01-01)